Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
Holland C. Detke, Brian A. Millen, Qi Zhang, et al.
Headache The Journal of Head and Face Pain (2019) Vol. 60, Iss. 2, pp. 348-359
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 247
Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
European Journal of Neurology (2022) Vol. 30, Iss. 1, pp. 224-234
Open Access | Times Cited: 39
CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention
Edoardo Caronna, Alicia Alpuente, Marta Torres‐Ferrús, et al.
Handbook of clinical neurology (2024), pp. 107-124
Closed Access | Times Cited: 10
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention
Jean Schoenen, Maïté Manise, Romain Nonis, et al.
Revue Neurologique (2020) Vol. 176, Iss. 10, pp. 788-803
Open Access | Times Cited: 51
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
Todd J. Schwedt, Richard B. Lipton, Jessica Ailani, et al.
Cephalalgia (2021) Vol. 42, Iss. 1, pp. 3-11
Open Access | Times Cited: 49
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
David W. Dodick, Christopher Gottschalk, Roger Cady, et al.
Headache The Journal of Head and Face Pain (2020) Vol. 60, Iss. 10, pp. 2220-2231
Open Access | Times Cited: 41
Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: Results from a retrospective case series support individual treatment attempts
Ruth Ruscheweyh, Gregor Broessner, Gudrun Goßrau, et al.
Cephalalgia (2020) Vol. 40, Iss. 14, pp. 1574-1584
Open Access | Times Cited: 40
Unmet Needs in the Acute Treatment of Migraine
Enrico Bentivegna, Silvia Galastri, Dilara Onan, et al.
Advances in Therapy (2023) Vol. 41, Iss. 1, pp. 1-13
Open Access | Times Cited: 14
Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation
Wanakorn Rattanawong, Prakit Anukoolwittaya, Akarin Hiransuthikul, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
Todd J. Schwedt, Dulanji Kuruppu, Yanhong Dong, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 26
Evidence-based guidelines for the pharmacological treatment of migraine
Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment
Todd J. Schwedt, Ashley Martin, Steven Kymes, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 4, pp. 484-493
Open Access | Times Cited: 9
Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome
Marta Torres‐Ferrús, Victor J Gallardo, Alicia Alpuente, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 7, pp. 1937-1944
Closed Access | Times Cited: 8
Calcitonin-gene-related peptide pathway mAbs and migraine prevention
Koen Paemeleire, Antoinette MaassenVanDenBrink
Current Opinion in Neurology (2018) Vol. 31, Iss. 3, pp. 274-280
Closed Access | Times Cited: 25
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients
Takao Takeshima, Masami Nakai, Yoshiyuki Shibasaki, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Treatment satisfaction with calcitonin gene‐related peptide monoclonal antibodies as a new patient‐reported outcome measure: A real‐life experience in migraine
A. López-Bravo, Antonio Oliveros‐Cid, Laura Sevillano‐Orte
Acta Neurologica Scandinavica (2022) Vol. 145, Iss. 6, pp. 669-675
Open Access | Times Cited: 12
Status migrainosus
Salwa Kamourieh, Todd D. Rozen, JANE ANDERSON
Handbook of clinical neurology (2024), pp. 413-439
Closed Access | Times Cited: 2
Preventive Treatment of Migraine
Richard B. Lipton
CONTINUUM Lifelong Learning in Neurology (2024) Vol. 30, Iss. 2, pp. 364-378
Closed Access | Times Cited: 2
Early Improvements With Atogepant for the Preventive Treatment of Migraine
Richard B. Lipton, Pranav Gandhi, Cristina Tassorelli, et al.
Neurology (2024) Vol. 104, Iss. 2
Closed Access | Times Cited: 2
Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
Dulanji Kuruppu, James North, Amy J. Kovacik, et al.
Advances in Therapy (2021) Vol. 38, Iss. 3, pp. 1614-1626
Open Access | Times Cited: 15
Patient preference for early onset of efficacy of preventive migraine treatments
Jessica Ailani, Paul Winner, Ann Hartry, et al.
Headache The Journal of Head and Face Pain (2022) Vol. 62, Iss. 3, pp. 374-382
Open Access | Times Cited: 11
Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
Dawn C. Buse, Paul Winner, Larry Charleston, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 10
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review
Christopher Gottschalk, Dawn C. Buse, Michael J. Marmura, et al.
Therapeutic Advances in Neurological Disorders (2022) Vol. 15, pp. 175628642210959-175628642210959
Open Access | Times Cited: 10
Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE
Taoufik Alsaadi, Deeb Maxwell Kayed, Abubaker Almadani, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 6, pp. 1845-1865
Open Access | Times Cited: 5
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
Xiuyuan Zhao, Xiaolin Xu, Qingyun Li
Journal of Neurology (2020) Vol. 268, Iss. 7, pp. 2364-2376
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top